top of page
Website Translator
FDA Approves Novartis' Adakveo for Pain Events Associated with Sickle Cell Disease
The U.S.Food and Drug Administration (FDA)approvedNovartis’ Adakveo (crizanlizumab) to decrease the frequency of vaso-occlusive crises...
SCDF Staff
Feb 21, 20242 min read
193
FDA Approves Oxbryta™, First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Oxbryta (voxelotor), a first sickle cell treatment that works to stop the sickling and destruction of red blood cells that mark this...
SCDF Staff
Feb 21, 20243 min read
389
bottom of page